Literature DB >> 11181547

Receptor activator of nuclear factor-kappa b ligand activates nuclear factor-kappa b in osteoclast precursors.

S Wei1, S L Teitelbaum, M W Wang, F P Ross.   

Abstract

Receptor activator of nuclear factor-kappa B ligand [RANK ligand (RANK-L)] stimulates mature osteoclasts to resorb bone, a process associated with NF-kappa B activation. RANK-L also prompts macrophages to develop the osteoclast phenotype. Although NF-kappa B is essential for osteoclast differentiation, it is not known whether RANK-L activates this transcription complex in osteoclast precursors. We report that RANK-L rapidly induces NF-kappa B activation in both authentic osteoclast precursors, namely bone marrow macrophages, and RAW 264.7 cells, a murine macrophage line also capable of RANK-L-mediated osteoclastogenesis. Supershift studies reveal the RANK-L-induced DNA binding moiety contains p50/p65, the most common NF-kappa B complex. Subcellular translocation of p50 and p65 subunits is confirmed by Western blots and immunofluorescence analysis. RANK-L activates NF-kappa B in both bone marrow macrophages and RAW 264.7 cells by serine phosphorylation of I kappa B alpha within 5 min, resulting in rapid I kappa B alpha degradation and resynthesis. Attesting to function, RANK-L treatment of RAW 264.7 cells transiently transfected with a plasmid containing NF-kappa B consensus elements linked to luciferase greatly enhances reporter activity. Our data suggest that activation of the NF-kappa B pathway is an integral component of RANK-L-induced osteoclast differentiation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181547     DOI: 10.1210/endo.142.3.8031

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  31 in total

1.  Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-κB and NF-κB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis.

Authors:  Ji H Kim; Subash C Gupta; Byoungduck Park; Vivek R Yadav; Bharat B Aggarwal
Journal:  Mol Nutr Food Res       Date:  2011-12-07       Impact factor: 5.914

2.  Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signaling.

Authors:  Bokyung Sung; Sung-Gook Cho; Mingyao Liu; Bharat B Aggarwal
Journal:  Int J Cancer       Date:  2011-03-11       Impact factor: 7.396

3.  Thiocolchicoside suppresses osteoclastogenesis induced by RANKL and cancer cells through inhibition of inflammatory pathways: a new use for an old drug.

Authors:  Simone Reuter; Subash C Gupta; Kanokkarn Phromnoi; Bharat B Aggarwal
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

4.  Aspirin inhibits osteoclastogenesis by suppressing the activation of NF-κB and MAPKs in RANKL-induced RAW264.7 cells.

Authors:  Yan-Ping Zeng; Chao Yang; Yuan Li; Yong Fan; Hong-Jun Yang; Bin Liu; Hong-Xun Sang
Journal:  Mol Med Rep       Date:  2016-06-30       Impact factor: 2.952

5.  Cloning and characterization of osteoclast precursors from the RAW264.7 cell line.

Authors:  Bethany L V Cuetara; Tania N Crotti; Anthony J O'Donoghue; Kevin P McHugh
Journal:  In Vitro Cell Dev Biol Anim       Date:  2006 Jul-Aug       Impact factor: 2.416

6.  Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6.

Authors:  Junko Mizukami; Giichi Takaesu; Hiroyuki Akatsuka; Hiroaki Sakurai; Jun Ninomiya-Tsuji; Kunihiro Matsumoto; Naoki Sakurai
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

Review 7.  Mechanisms modulating inflammatory osteolysis: a review with insights into therapeutic targets.

Authors:  Shi Wei; Gene P Siegal
Journal:  Pathol Res Pract       Date:  2008-08-30       Impact factor: 3.250

8.  WITHDRAWN: Cardamonin Inhibits Osteoclastogenesis Induced by Tumor Cells Through Interruption of the Signaling Pathway Activated by Receptor Activator of NF-κB Ligand.

Authors:  Vivek R Yadav; Sahdeo Prasad; Simone Reuter; Bokyung Sung; Norio Yamamoto; Akira Murakami; Bharat B Aggarwal
Journal:  Cancer Lett       Date:  2011-12-17       Impact factor: 8.679

9.  Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss.

Authors:  Julia Barsony; Yoshihisa Sugimura; Joseph G Verbalis
Journal:  J Biol Chem       Date:  2010-12-06       Impact factor: 5.157

10.  The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling.

Authors:  Michael W-H Wang; Shi Wei; Roberta Faccio; Sunao Takeshita; Pablo Tebas; William G Powderly; Steven L Teitelbaum; F Patrick Ross
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.